Top

Armeen Mahvash, M.D.

Department of Interventional Radiology, Division of Diagnostic Imaging

About Dr. Armeen Mahvash

Dr. Armeen Mahvash joined MD Anderson in 2006 as an Assistant Professor in the Department of Interventional Radiology, Division of Diagnostic Imaging. He was subsequently promoted to Associate professor in 2012. Dr. Mahvash was also Faculty of the... Year for MD Anderson Cancer Center, Interventional Radiology in 2014. Dr. Mahvash’s research interests include combining Local and Regional Interventional Therapies with Systemic Therapy, Phase III clinical trial evaluating TheraSphere in patients with metastatic colorectal carcinoma of the liver who have failed first line chemotherapy, Sorafenib and yttrium-90 glass microspheres for advanced hepatocellular carcinoma, Selective internal radiation therapy (SIRT) with yttrium glass and resin microspheres, SIRT Tumor Dosimetry. His clinical interests include s elective internal radiation therapy (SIRT) with yttrium glass and resin microspheres, Colorectal cancer, Hepatocellular cancer, Cholangiocarcinoma.

Primary Appointment

Professor, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Assistant Professor, Department of Diagnostic and Interventional Imaging, The University of Texas Medical School at Houston, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1999	Baylor College of Medicine, Houston, Texas, US, MD
1991	University of Texas at Austin, Austin, Texas, US, Mechanical Engineering, BS

Postgraduate Training

2005-2006	Clinical Fellowship, Interventional and Vascular Radiology, The University of Texas Medical School at Houston, Houston, Texas
2000-2004	Clinical Residency, Diagnostic Radiology, The University of Texas Health Science Center at Houston, Houston, Texas
1999-2000	Transitional Internship, John Peter Smith Hospital, Tarrant County Hospital District, Fort Worth, Texas

Board Certifications

2007	American Board of Radiology, Certificate of Added Qualification in Vascular and Interventional Radiology
2004	American Board of Radiology

Experience & Service

Academic Appointments

Associate Professor, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019

Associate Professor, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2013

Assistant Professor, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2012

Assistant Professor, Department of Diagnostic and Interventional Imaging, The University of Texas Medical School at Houston, Houston, TX, 2006 - 2013

Other Appointments/Responsibilities

Committee Member, IRB #1, Houston, TX, TX, 2020 - 2021

Committee Member, SRC #2, Houston, TX, TX, 2020 - 2021

Co-Chair, Y90 Users Committee, Houston, TX, 2016 - Present

Member, Fluoroscopy Privileging Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Member, Interventional Oncology Working Group, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - Present

Institutional Committee Activities

Member, Hepatocellular Carcinoma Treatment Algorithm Development Workgroup, 2022 - 2023

Physician Representative, Patient Radiation Dose Committee, 2006 - Present

Honors & Awards

2023	Best Scientific Abstract, Global Embolization Oncology Symposium Technologies - GEST 2023
2021	DI - Interventional Radiology Outstanding Clinician Award, Patient Care, The University of Texas MD Anderson Cancer Center, Division of Diagnostic Imaging
2020	First Place Recognition for Celebrate Solutions Quality Improvement Poster Presentation, The University of Texas MD Anderson Cancer Center, Division of Diagnostic Imaging
2016	Best Poster Winner - Imaging Category, World Conference of Interventional Radiology (WCIO) 2016
2015	Third Place Recognition for Poster Presentation, Society of Nuclear Medicine
2014	IR Faculty of the Year, The University of Texas MD Anderson Cancer Center, Interventional Radiology
2012	Radiopharmaceutical Track Poster Award, Society of Nuclear Medicine and Molecular Imaging

Professional Memberships

American Roentgen Ray Society

2006 - Present

Houston Radiological Society

2006 - Present

Society of Interventional Radiology

2006 - Present

Harris County Medical Society

2006 - Present

Texas Medical Association

2006 - Present

Selected Publications

Peer-Reviewed Articles

Morris VK, Liu S, Lin K, Zhu H, Prasad S, Mahvash A, Bhosale P, Sun B, Parra ER, Wistuba I, Peddireddy A, Yao J, Mendoza-Perez J, Knafl M, Woodman SE, Eng C, Halperin D. Phase II trial of atezolizumab and bevacizumab for treatment of HPV-positive unresectable or metastatic squamous cell carcinoma of the anal canal. Clin Cancer Res. e-Pub 2025. PMID: 40019482.
Haddad A, Khavandi MM, Lendoire M, Belkacem A, Chiang YJ, Gupta S, Tam A, Odisio BC, Mahvash A, Abdelsalam ME, Lin E, Kuban J, Newhook TE, Tran Cao HS, Tzeng CD, Huang SY, Vauthey JN, Habibollahi P. ASO Visual Abstract: Propensity Score-Matched Analysis of Liver Venous Deprivation and Portal Vein Embolization before Planned Hepatectomy in Patients with Extensive Colorectal Liver Metastases and High-risk Factors for Inadequate Regeneration. Ann Surg Oncol, 2025. e-Pub 2025. PMID: 39838241.
Haddad A, Khavandi MM, Lendoire M, Acidi B, Chiang YJ, Gupta S, Tam A, Odisio BC, Mahvash A, Abdelsalam ME, Lin E, Kuban J, Newhook TE, Tran Cao HS, Tzeng CD, Huang SY, Vauthey JN, Habibollahi P. Propensity score-matched analysis of liver venous deprivation and portal vein embolization before planned hepatectomy in patients with extensive colorectal liver metastases and high-risk factors for inadequate regeneration. Ann Surg Oncol 32(3):1752-1761, 2024. e-Pub 2024. PMID: 39633174.
Kappadath SC, Henry EC, Lopez BP, Mahvash A. Quantitative evaluation of (90)Y-PET/CT and (90)Y-SPECT/CT-based dosimetry following Yttrium-90 radioembolization. Med Phys 51(9):6061-6074, 2024. e-Pub 2024. PMID: 38781554.
Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark 41(1):83-91, 2024. e-Pub 2024. PMID: 39269823.
Henry EC, Mahvash A, Lopez BP, Kappadath SC. A comparison of methods for in vivo activity and absorbed dose quantification with PET/CT following yttrium-90 radioembolization. Med Phys 51(9):6034-6045, 2024. e-Pub 2024. PMID: 38772046.
Tran Cao HS, Witt RG, Elsayes KM, Baiomy AA, Xiao L, Palmquist S, Lee SS, Mohamed YI, Mahvash A, Tzeng CD, Chun YS, Koay EJ, Rashid A, Hassan MM, Yao JC, Vauthey JN, Kaseb AO. Development of a novel comprehensive hepatocellular carcinoma outcome prognostic scoring system with integration of imaging features. Oncologist 29(6):e803-e810, 2024. e-Pub 2024. PMID: 38159256.
Lam M, Garin E, Palard-Novello X, Mahvash A, Kappadath C, Haste P, Tann M, Herrmann K, Barbato F, Geller B, Schaefer N, Denys A, Dreher M, Fowers KD, Gates V, Salem R. Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 51(1):245-257, 2023. e-Pub 2023. PMID: 37698645.
Henry EC, Lopez B, Mahvash A, Thomas MA, Kappadath SC. Predicting the net administered activity in 90 Y-radioembolization patients from post-procedure 90 Y-SPECT/CT. Med Phys 50(11):7003-7015, 2023. e-Pub 2023. PMID: 37272198.
Lin YM, Fellman BM, Taiji R, Paolucci I, Silva JAM, Koay EJ, Avritscher R, Mahvash A, Holliday EB, Lee SS, Kaseb AO, Das P, Vauthey JN, Odisio BC. Salvage locoregional therapy following progression after radiotherapy for hepatocellular carcinoma is associated with improved outcomes. J Gastrointest Surg 27(9):1867-1875, 2023. e-Pub 2023. PMID: 37268830.
Moawad AW, Morshid A, Khalaf AM, Elmohr MM, Hazle JD, Fuentes D, Badawy M, Kaseb AO, Hassan M, Mahvash A, Szklaruk J, Qayyum A, Abusaif A, Bennett WC, Nolan TS, Camp B, Elsayes KM. Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation. Sci Data 10(1):33, 2023. e-Pub 2023. PMID: 36653372.
Taiji R, Lin YM, Chintalapani G, Lin EY, Huang SY, Mahvash A, Avritscher R, Liu CA, Lee RC, Resende V, Nishiofuku H, Tanaka T, Kichikawa K, Klotz E, Gupta S, Odisio BC. A novel method for predicting hepatocellular carcinoma response to chemoembolization using an intraprocedural CT hepatic arteriography-based enhancement mapping: a proof-of-concept analysis. Eur Radiol Exp 7(1):4, 2023. e-Pub 2023. PMID: 36717474.
Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget 13(1):1314-1321, 2022. e-Pub 2022. PMID: 36473155.
Habibollahi P, Odisio BC, Gurusamy V, Kuban JD, Avritscher R, Abdelsalam ME, Chasen BA, Murthy R, Mahvash A. Temporary reversal of hepatoenteric collaterals during 90Y radioembolization planning and administration. Curr Oncol 29(12):9582-9592, 2022. e-Pub 2022. PMID: 36547167.
Lopez BP, Mahvash A, Long JP, Lam MGEH, Kappadath SC. Factors modulating 99m Tc-MAA planar lung dosimetry for 90 Y radioembolization. J Appl Clin Med Phys 23(12):e13734, 2022. e-Pub 2022. PMID: 35906892.
Agahi KN, Mahvash A, Abdelsalam ME. Hepatic abscess following yttrium-90 radioembolization in patients with surgical bilioenteric anastomosis or compromised sphincter of Oddi: A tertiary cancer center experience. Curr Oncol 29(10):7051-7058, 2022. e-Pub 2022. PMID: 36290830.
Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: A nonrandomized clinical trial. JAMA Oncol 8(6):904-909, 2022. e-Pub 2022. PMID: 35389428.
Mahvash A, Chartier S, Turco M, Habib P, Griffith S, Brown S, Kappadath SC. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90 Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterol 22(1):151, 2022. e-Pub 2022. PMID: 35346070.
Honan KA, Hassan S, Deswal A, Herrmann J, Song J, Monlezun D, Halperin D, Mahvash A, Dasari A, Koutroumpakis E, Akay M, Balanescu DV, de Armas IS, Patel M, Nathan S, Kar B, Marmagkiolis K, Lopez-Mattei J, Patel J, Gregoric I, Yao J, Iliescu CA. Bioprosthetic valve monitoring in patients with carcinoid heart disease. Front Cardiovasc Med 9:1072890, 2022. e-Pub 2022. PMID: 36712267.
Nishioka Y, Odisio BC, Velasco JD, Ninan E, Huang SY, Mahvash A, Tzeng CD, Tran Cao HS, Gupta S, Vauthey JN. Fast-track two-stage hepatectomy by concurrent portal vein embolization at first-stage hepatectomy in hybrid interventional radiology / operating suite. Surg Oncol 39:101648, 2021. e-Pub 2021. PMID: 34438236.
Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 27(47):8166-8181, 2021. e-Pub 2021. PMID: 35068861.
Strosberg JR, El-Haddad G, Al-Toubah T, Reidy D, Ziv E, Mahvash A, Dasari A, Philip P, Soulen MC. Radioembolization versus bland or chemoembolization for liver-dominant neuroendocrine tumors: Is it an either/or question?. J Nucl Med 62(12):1669-1671, 2021. e-Pub 2021. PMID: 34556527.
Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG, Herrmann K, Brown E, Zuckerman D, Wilson G, Kim TY, Weaver A, Ross P, Harris WP, Graham J, Mills J, Yubero Esteban A, Johnson MS, Sofocleous CT, Padia SA, Lewandowski RJ, Garin E, Sinclair P, Salem R, Investigators E. Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial. J Clin Oncol 39(35):3897-3907, 2021. e-Pub 2021. PMID: 34541864.
Whitlock RS, Loo C, Patel K, Bista R, Goss JA, Heczey A, Khan O, Lopez-Terrada D, Masand P, Nguyen H, Mahvash A, Vasudevan SA, Kukreja K. Transarterial radioembolization treatment as a bridge to surgical resection in pediatric hepatocellular carcinoma. J Pediatr Hematol Oncol 43(8):e1181-e1185, 2021. e-Pub 2021. PMID: 33769387.
Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, safety and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
Levillain H, Bagni O, Deroose CM, Dieudonné A, Gnesin S, Grosser OS, Kappadath SC, Kennedy A, Kokabi N, Liu DM, Madoff DC, Mahvash A, Martinez de la Cuesta A, Ng DCE, Paprottka PM, Pettinato C, Rodríguez-Fraile M, Salem R, Sangro B, Strigari L, Sze DY, de Wit van der Veen BJ, Flamen P. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 48(5):1570-1584, 2021. e-Pub 2021. PMID: 33433699.
Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A prospective phase II study of safety and efficacy of sorafenib followed by 90Y glass microspheres for patients with advanced or metastatic hepatocellular carcinoma. J Hepatocell Carcinoma 8:1129-1145, 2021. e-Pub 2021. PMID: 34527608.
Jácome AA, Ohinata A, Mahvash A, Overman MJ, Kee B, Fogelman D, Morris VK, Johnson B, Rothschild ND, Wolff RA, Eng C. Bevacizumab does not influence the efficacy of partial splenic embolization in the management of chemotherapy-induced hypersplenism. Clin Colorectal Cancer 19(4):e189-e199, 2020. e-Pub 2020. PMID: 32680816.
Thomas MA, Mahvash A, Abdelsalam M, Kaseb AO, Kappadath SC. Planning dosimetry for 90 Y radioembolization with glass microspheres: Evaluating the fidelity of 99m Tc-MAA and partition model predictions. Med Phys 47(10):5333-5342, 2020. e-Pub 2020. PMID: 32790882.
Hill A, Elakkad A, Kuban J, Sabir S, Odisio B, Huang SY, Mahvash A, Miller E, Kroll MH, Overman M, Tam AL, Gupta S, Sheth RA. Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia. Abdom Radiol (NY) 45(9):2886-2894, 2020. e-Pub 2020. PMID: 32314004.
Buettner S, Braat AJAT, Margonis GA, Brown DB, Taylor KB, Borgmann AJ, Kappadath SC, Mahvash A, IJzermans JNM, Weiss MJ, Lamarca A, Bell JK, Valle JW, Hagendoorn J, Koerkamp BG, Sze DY, Lam MGEH. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: A multicenter retrospective analysis. J Vasc Interv Radiol 31(7):1035-1043.e2, 2020. e-Pub 2020. PMID: 32473757.
Niekamp AS, Huang SY, Mahvash A, Odisio BC, Ahrar K, Tzeng CD, Vauthey JN. Hepatic vein embolization after portal vein embolization to induce additional liver hypertrophy in patients with metastatic colorectal carcinoma. Eur Radiol 30(7):3862-3868, 2020. e-Pub 2020. PMID: 32144462.
Braat AJAT, Ahmadzadehfar H, Kappadath SC, Stothers CL, Frilling A, Deroose CM, Flamen P, Brown DB, Sze DY, Mahvash A, Lam MGEH. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol 43(2):246-253, 2020. e-Pub 2020. PMID: 31646375.
Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival outcomes for yttrium-90 transarterial radioembolization with and without sorafenib for unresectable hepatocellular carcinoma patients. J Hepatocell Carcinoma 7:117-131, 2020. e-Pub 2020. PMID: 32984089.
Lopez B, Mahvash A, MGEH L, Kappadath SC. Calculation of lung mean dose and quantification of error for 90 Y-microsphere radioembolization using 99m Tc-MAA SPECT/CT and diagnostic chest CT. Med Phys 46(9):3929-3940, 2019. e-Pub 2019. PMID: 31063600.
Morshid A, Elsayes KM, Khalaf AM, Elmohr MM, Yu J, Kaseb AO, Hassan M, Mahvash A, Wang Z, Hazle JD, Fuentes D. A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell 1(5), 2019. e-Pub 2019. PMID: 31858078.
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78, 2019. e-Pub 2019. PMID: 31277699.
Braat AJAT, Kappadath SC, Ahmadzadehfar H, Stothers CL, Frilling A, Deroose CM, Flamen P, Brown DB, Sze DY, Mahvash A, Lam MGEH. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases: International multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol 42(3):413-425, 2019. e-Pub 2019. PMID: 30603975.
Odisio BC, Krampitz GW, Murthy R, Mahvash A, Javle M, Vauthey JN. Preoperative drainage for perihilar cholangiocarcinoma. Lancet Gastroenterol Hepatol 4(1):10-11, 2019. e-Pub 2019. PMID: 30527574.
Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular carcinoma tumor dose response after 90Y-radioembolization with glass microspheres using 90Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys 102(2):451-461, 2018. e-Pub 2018. PMID: 30191875.
Sheth RA, Sabir SH, Parmet P, Amin R, Kuban JD, Huang SY, Mahvash A, Fogelman D, Javle M, Wallace MJ. Portomesenteric venous stenting for palliation of ascites and variceal bleeding caused by prehepatic portal hypertension. Oncologist 23(6):712-718, 2018. e-Pub 2018. PMID: 29284759.
Niekamp A, Abdel-Wahab R, Kuban J, Odisio BC, Mahvash A, Hassan MM, Qayyum A, Kaseb A, Sheth RA. Baseline apparent diffusion coefficient as a predictor of response to liver-directed therapies in hepatocellular carcinoma. J Clin Med 7(4), 2018. e-Pub 2018. PMID: 29661994.
Braat AJAT, Kappadath SC, Bruijnen RCG, van den Hoven AF, Mahvash A, HWAM DJ, Lam MGEH. Adequate SIRT activity dose is as important as adequate chemotherapy dose. Lancet Oncol 18(11):e636, 2017. e-Pub 2017. PMID: 29208390.
Abdelsalam ME, Mahvash A, Madoff DC, Odisio BC, Kuban JD, Avritscher R, Murthy R. Radioembolization in colorectal metastases: A review. Digestive Disease Interventions 01(03):208-217, 2017. e-Pub 2017.
Odisio BC, Cox VL, Faria SC, Yamashita S, Shi X, Ensor J, Jones AK, Mahvash A, Gupta S, Tam AL, Vauthey JN, Murthy R. Prognostic value of incidental hypervascular micronodules detected on cone-beam computed tomography angiography of patients with liver metastasis. Eur Radiol 27(11):4837-4845, 2017. e-Pub 2017. PMID: 28484824.
Litwin RJ, Huang SY, Sabir SH, Hoang QB, Ahrar K, Ahrar J, Tam AL, Mahvash A, Ensor JE, Kroll M, Gupta S. Impact of an inferior vena cava filter retrieval algorithm on filter retrieval rates in a cancer population. J Vasc Surg Venous Lymphat Disord 5(5):689-697, 2017. e-Pub 2017. PMID: 28818223.
Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-453, 2017. e-Pub 2017. PMID: 28223062.
Ahrar JU, Gupta S, Ensor JE, Mahvash A, Sabir SH, Steele JR, McRae SE, Avritscher R, Huang SY, Odisio BC, Murthy R, Ahrar K, Wallace MJ, Tam AL. Efficacy of a self-expanding tract sealant device in the reduction of pneumothorax and chest tube placement rates after percutaneous lung biopsy: A matched controlled study using propensity score analysis. Cardiovasc Intervent Radiol 40(2):270-276, 2017. e-Pub 2017. PMID: 27826786.
Gupta N, Patel A, Ensor J, Ahrar K, Ahrar J, Tam A, Odisio B, Huang S, Murthy R, Mahvash A, Avritscher R, McRae S, Sabir S, Wallace M, Matin S, Gupta S. Multiple renal artery pseudoaneurysms in patients undergoing renal artery embolization following partial nephrectomy: Correlation with RENAL nephrometry scores. Cardiovasc Intervent Radiol 40(2):202-209, 2017. e-Pub 2017. PMID: 27681271.
Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO. Natural history of T1N0M0 hepatocellular carcinoma: Large-scale study in the United States. Oncology 93(4):233-242, 2017. e-Pub 2017. PMID: 28683459.
Mikell JK, Mahvash A, Siman W, Baladandayuthapani V, Mourtada F, Kappadath SC. Selective internal radiation therapy with yttrium-90 glass microspheres: Biases and uncertainties in absorbed dose calculations between clinical dosimetry models. Int J Radiat Oncol Biol Phys 96(4):888-896, 2016. e-Pub 2016. PMID: 27623307.
Passot G, Odisio BC, Zorzi D, Mahvash A, Gupta S, Wallace MJ, Kim BJ, Yamashita S, Conrad C, Aloia TA, Vauthey JN, Chun YS. Eradication of missing liver metastases after fiducial placement. J Gastrointest Surg 20(6):1173-8, 2016. e-Pub 2016. PMID: 26791387.
Abdelsalam ME, Mahvash A, Avritscher R, McRae SE, Odisio BC. Balloon-assisted flow diversion and selective catheterization of target vessels for hepatic transarterial embolization. J Vasc Interv Radiol 27(2):283-5, 2016. e-Pub 2016. PMID: 26830942.
Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 3:1-7, 2016. e-Pub 2016. PMID: 27574586.
Kuban JD, Tam AL, Huang SY, Ensor JE, Philip AS, Chen GJ, Ahrar J, Murthy R, Avritscher R, Madoff DC, Mahvash A, Ahrar K, Wallace MJ, Nachiappan AC, Gupta S. The effect of needle gauge on the risk of pneumothorax and chest tube placement after percutaneous computed tomographic (CT)-guided lung biopsy. Cardiovasc Intervent Radiol 38(6):1595-602, 2015. e-Pub 2015. PMID: 25920917.
Mikell JK, Mahvash A, Siman W, Mourtada F, Kappadath SC. Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for 90Y microsphere selective internal radiation therapy. EJNMMI Phys 2(1):16, 2015. e-Pub 2015. PMID: 26501817.
Steele JR, Jones AK, Ninan EP, Clarke RK, Odisio BC, Avritscher R, Murthy R, Mahvash A. Why bundled payments could drive innovation: An example from interventional oncology. J Oncol Pract 11(2):e199-205, 2015. e-Pub 2015. PMID: 25604596.
Shindoh J, Tzeng CW, Aloia TA, Curley SA, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN. Safety and efficacy of portal vein embolization before planned major or extended hepatectomy: an institutional experience of 358 patients. J Gastrointest Surg 18(1):45-51, 2014. e-Pub 2014. PMID: 24129824.
Enriquez J, Javadi S, Murthy R, Ensor J, Mahvash A, Abdelsalam ME, Madoff DC, Wallace MJ, Avritscher R. Gastroduodenal artery recanalization after transcatheter fibered coil embolization for prevention of hepaticoenteric flow: Incidence and predisposing technical factors in 142 patients. Acta Radiol 54(7):790-4, 2013. e-Pub 2013. PMID: 23535183.
Shindoh J, Tzeng CW, Aloia TA, Curley SA, Zimmitti G, Wei SH, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 20(8):2493-500, 2013. e-Pub 2013. PMID: 23377564.
Shindoh J, Vauthey JN, Zimmitti G, Curley SA, Huang SY, Mahvash A, Gupta S, Wallace MJ, Aloia TA. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg 217(1):126-33, 2013. e-Pub 2013. PMID: 23632095.
Neperud J, Mahvash A, Garg N, Murthy R, Szklaruk J. Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy?. World J Radiol 5(6):241-7, 2013. e-Pub 2013. PMID: 23807902.
Shindoh J, Truty MJ, Aloia TA, Curley SA, Zimmitti G, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: Toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 216(2):201-9, 2013. e-Pub 2013. PMID: 23219349.
Smith J, Murthy R, Lahoti A, Odisio B, Avritscher R, Chasen B, Mahvash A. Temporary balloon occlusion of the common hepatic artery for yttrium-90 glass microspheres administration in a patient with hepatocellular cancer and renal insufficiency. Case Rep Radiol 2013(Article ID 560758):1-3, 2013. e-Pub 2013. PMID: 23710405.
Jones AK, Mahvash A. Evaluation of the potential utility of flat panel CT for quantifying relative contrast enhancement. Med Phys 39(7):4149-54, 2012. e-Pub 2012. PMID: 22830748.
Mahvash A, Zaer N, Shaw C, Chasen B, Avritscher R, Murthy R. Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals. J Vasc Interv Radiol 23(2):277-80, 2012. e-Pub 2012. PMID: 22264555.
Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SO. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant 17(10):1551-5, 2011. e-Pub 2011. PMID: 21396475.
Zalinski S, Abdalla EK, Mahvash A, Vauthey JN. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol 16(5):1208-11, 2009. e-Pub 2009. PMID: 19214636.
Murthy R, Mutha P, Madoff DC, Mahvash A, Erwin W. Establishment of the radiation effect of yttrium-90 microspheres: Role of C-arm CT. J Vasc Interv Radiol 20(3):422-424, 2009. e-Pub 2009. PMID: 19167244.
Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 112(10):2283-8, 2008. e-Pub 2008. PMID: 18344210.

Manuals, Teaching Aids, Other Teaching Publications

Fleckenstein ON, Kaur H, Koay E, Kuban JD, Lee S, Mahvash A, Nguyen V, Nguyen V, Odisio BC, Yedururi S, Zhang M. Hepatocellular Carcinoma Treatment Algorithm, 2023.

Abstracts

Mahvash A. A prospective, multicenter, open-label, clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for treatment of unresectable hepatocellular carcinoma (HCC): Doorway90. Americas Hepato-Pancreato-Biliary Association (AHPBA) 2021 Annual Meeting, 2021. e-Pub 2021.
Kappadath SC, Lopez BP, Mahvash A. Organ doses following intra-hepatic-arterial administration of 99mTc-MAA in planning dosimetry for 90Y-SIRT. Med Phys 48(6):e141, 2021. e-Pub 2021.
Kappadath SC, Balagopal A, Mahvash A. Uncertainties in geometric-mean based lung shunt fraction for 90Y radioembolization. Eur J Nucl Med Mol Imaging 44(Suppl 2):5800, 2017. e-Pub 2017.
Kaseb AO, Abdel-Wahab R, Murthy R, Hassan M, Singh Raghav KP, Xiao L, Morris J, Avritscher R, Odisio BC, Ohaji C, Wolff RA, Yao JC, Mahvash A. A phase II study of sorafenib and yttrium-90 glass microspheres for advanced hepatocellular carcinoma, BCLC stage C. 2017 ASCO Annual Meeting, 2016. e-Pub 2016.
Odisio BC, Cox VL, Mahvash A, Xiao S, Ensor J, Wallace MJ, Jones AK, Gupta S, Tam AL, Murthy R, Faria SC. Incidentally-found miliary liver lesions on Cone-beam CT angiography: Higher risk for metastatic hepatic disease progression. 2016 WCIO, 2016. e-Pub 2016.
Mahvash A, Justin M, Siman W, Odisio BC, Murthy R. Quantifying differences in tumor uptake between planning 99mTc-MAA and post-therapy 90Y microsphere SPECT/CT using the balloon occlusion technique for common hepatic artery administration. SIR Annual Meeting 2016, 2016. e-Pub 2016.
Mikell J, Mahvash A, Siman W, Mourtada F, Kappadath SC. Poster - Differences between four voxel-based dosimetry methods for 90Y microsphere therapy. Society of Nuclear Medicine Annual Meeting, 2015. e-Pub 2015.
Mahvash A, Odisio BC, Avritscher R, Chasen B, Murthy R. Temporary balloon occlusion of the common hepatic artery during Y90 radioembolization planning and treatment in patients with patent hepatoenteric collaterals. J Vasc Interv Radiol, 2015. e-Pub 2015.
Mikell J, Mahvash A, Siman W, Mourtada F, Kappadath SC. Poster - Biases and variability in partition model absorbed doses following 90Y microsphere therapy. Society of Nuclear Medicine 2015 Annual Meeting, 2015. e-Pub 2015.
Murthy R, Subbiah S, Mahvash A, Odisio BC, Gupta S, Ahrar J, Sabir Sh, Huang S, Bosch M. Image-guided autologous dendritic cell vaccination in advanced cancer: Technical aspects. Poster, 2015. e-Pub 2015.
Mikell J, Siman W, Mahvash A, Mourtada F, Kappadath S. Kernel based dosimetry for 90Y microsphere liver therapy using 90Y bremsstrahlung SPECT/CT. Medical Physicians 41(6):438, 2014. e-Pub 2014.
Black, Jones AK, Mahvash A, Odisio BC, Avritscher R, Ensor Jr J, Murthy R, Jr S, JR. Impact of a novel balloon occlusion technique on fluoroscopy time and radiation dose during Y90 radioembolization. Journal of Vascular and Interventional Radiology, 2014. e-Pub 2014.
Mikell J, Mourtada F, Mahvash A, Kappadath S. Characterization of tumor dose heterogeneity for 90Y microsphere therapies using voxel-based dosimetry. The Journal of Nuclear Medicine, 2014. e-Pub 2014.
Kappadath S, Mikell J, Mourtada F, Mahvash A. Voxel-based dosimetry and radiobiological modeling of HCC tumor response after 90Y microsphere therapy. The Journal of Nuclear Medicine, 2014. e-Pub 2014.
Kappadath S, Erwin W, Santiago G, Mahvash A. Implications of immediate versus delayed imaging for estimation of lung shunt in 90Y microsphere therapy planning. The Journal of Nuclear Medicine, 2014. e-Pub 2014.
Murthy R, Subbiah V, Mahvash A, Odisio B, Gupta S, Ahrar J, Bosch M. Phase 1 trial of image-guided vaccination of autologous dendritic cell in advanced cancer: Technical aspects, 2014. e-Pub 2014.
Mahvash A, Murthy R. Yttrium - 90 microsphere radioembolotheray for adolescent hepatic malignancies: Early experience at MD Anderson Cancer Center. 5th Pediatric Interventional Radiology Symposium, 2012. e-Pub 2012.
Maclellan C, Hobbs BP, Chasen B, Murthy R, Mahvash A, Kappadath SC. Absorbed dose differences in 90Y microsphere therapy between pre-treatment 99m Tc-MAA and post-treatment 90y scans. J Nucl Med 53 (Suppl)(1):323, 2012. e-Pub 2012.
Mahvash A, Moayyad J, Shreyaah S, Avritscher R, Murthy R. Y90 radioembolization in patients with compromise of the ampulla of vater. GEST 2012 U.S. Abstracts - JVIR:577.e12, 2012. e-Pub 2012.
Enriquez J, Javadi S, Murthy R, Ensor J, Mahvash A, Abdelsalam M, Madoff D, Wallace MJ, Avritscher R. Gastroduodenal artery recanalization after transcatheter coil occlusion for prevention of hepaticoenteric flow: Incidence and predisposing technical factors in 142 patients. J Vasc Interv Radiol 23(4):577.e4, 2012. e-Pub 2012.
Mahvash A, Shreyaah S, Chasen B, Avritscher R, Murthy R. Balloon-catheter occlusion technique for administration of Y90 microspheres in patients with patent hepatoenteric arteries. J Vasc Interv Radiol Supplement 23(3):567-568, 2012. e-Pub 2012.
Murthy R, Mahvash A, Avritscher R, Erwin W, Chasen B, Eng C. Yttrium microspheres with cetuximab plus irinotecan for patients with advanced colorectal cancer metastases to liver. J Clin Oncol 28(15S, Part I of II):30s, 2010. e-Pub 2010.

Book Chapters

Huang, SY, Tzeng, CD, Mahvash, A. Yttrium-90 Radioembolization for Metastatic Colorectal Cancer. In: Colorectal Liver Metastasis. 1, 397-406, 2022.
Mahvash, A, Murthy R. Balloon occlusion technique during Y90 radioembolization. In: Balloon Occlusion Technique During Y90 Radioembolization. In: Interventional and Endovascular Tips and Tricks of the Trade. Lowell Kahn and Bulent Arsian, 2018.
Mahvash A, Javadi S, Ahrar K. Embolotherapy in the management of renal cell carcinoma. In: Interventional Oncology Principles and Practice, 413-423, 2008.
Mahvash A, Wallace MJ. CT guided percutaneous needle aspiration and biopsy. In: Diagnosis and Staging of Lung Cancer: A Minimally Invasive Approach. People's Medical Publishing House - USA.

Letters to the Editor

de Sousa, LG, Liu, S, Bhosale, P, Altan, M, Darbonne, WC, Schulze, K, Dervin, S, Yun, C, Mahvash, A, Verma, A, Futreal, A, Gite, S, Parra Cuentas, ER, Cho, WC, Wistuba, II, Yao, JC, Woodman, SE, Halperin, DM, Ferrarotto, R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncology 151: 106747, 2024.
Arango NP, Nishioka Y, Velasco J, Mahvash A, Mehran RJ, Wang LS, Taggart MW, Vauthey JN, Odisio BC. Involution of hepatocellular neoplasm after embolization of a portosystemic vascular shunt in an adult with abernethy type II malformation. J Vasc Interv Radiol 32: 1391-1393, 2021.

Less